Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Alena, Pechonkina"'
Autor:
Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 161-185 (2022)
Abstract Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by estimated radiographic progression rate before baseline (BL) in patients with rheumatoid arthritis (RA) who had inadequate response to methotrex
Externí odkaz:
https://doaj.org/article/5ad3c011326f47e39cc3a991b6b2f59f
Autor:
Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 53-70 (2022)
Abstract Introduction This exploratory analysis of FINCH 1 (NCT02889796) examined filgotinib (FIL) efficacy and safety in a subgroup of patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX; MTX-IR) who had four poor pr
Externí odkaz:
https://doaj.org/article/d5f278750ece4369b8287f893aae3cee
Autor:
Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 71-72 (2023)
Externí odkaz:
https://doaj.org/article/482e0de723eb4725b687f0331d72bd59
Autor:
Elizabeth, Price, Michele, Bombardieri, Alan, Kivitz, Franziska, Matzkies, Oksana, Gurtovaya, Alena, Pechonkina, Wendy, Jiang, Bryan, Downie, Anubhav, Mathur, Afsaneh, Mozaffarian, Neelufar, Mozaffarian, J Eric, Gottenberg
Publikováno v:
Rheumatology. 61:4797-4808
Objective The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS. Methods This multicentre, double-blind study randomized patients with active primary or secondary SS [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b9dad1a67e0ad6b2078e508d4f78b2
https://doi.org/10.1093/rheumatology/keac167
https://doi.org/10.1093/rheumatology/keac167
Autor:
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Ying Guo, Chantal Tasset, John S Sundy, Tsutomu Takeuchi
Publikováno v:
Modern Rheumatology. 32:263-272
Objectives Evaluate the efficacy and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX). Methods Data from 147 Japanese patients in FINCH 1, a 52-week gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e7ff89e8749425f82fee2c3dc903b9
https://doi.org/10.1093/mr/roab030
https://doi.org/10.1093/mr/roab030
Autor:
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, René Westhovens, Daniel W T Ching, Osvaldo Daniel Messina, Gerd R Burmester, Mark Genovese, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Zhaoyu Yin, Qi Gong, Chantal Tasset, Tsutomu Takeuchi
Objectives To evaluate the long-term safety and efficacy of filgotinib (FIL) for Japanese patients with rheumatoid arthritis (RA) and limited/no prior methotrexate (MTX) exposure. We present a Japanese population subanalysis of a global randomised-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a001f3fe9d815badd3596629ad91672
https://lirias.kuleuven.be/handle/20.500.12942/700387
https://lirias.kuleuven.be/handle/20.500.12942/700387
Autor:
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash, Mark Genovese, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Qi Gong, Chantal Tasset, Tsutomu Takeuchi
Publikováno v:
Modern Rheumatology.
Objectives To present safety and efficacy of the JAK1 preferential inhibitor filgotinib in Japanese patients with prior inadequate response (IR) to methotrexate (MTX) from a 52-week randomised controlled parent study (PS) and long-term extension (LTE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::970d3b8f2d148761694f4dd81f1c0fad
https://doi.org/10.1093/mr/roac084
https://doi.org/10.1093/mr/roac084
Autor:
Bernard Combe, Yoshiya Tanaka, Paul Emery, Alena Pechonkina, Albert Kuo, Qi Gong, Katrien Van Beneden, Vijay Rajendran, Hendrik Schulze-Koops
Publikováno v:
Rheumatology. 61
Background/Aims The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. We assessed efficacy and safety of FIL in patients (pts) with inadequate response to M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::248209ab4d55864543fadbc0f49dd6b1
https://doi.org/10.1093/rheumatology/keac132.029
https://doi.org/10.1093/rheumatology/keac132.029
Autor:
Maya Buch, Tsutomu Takeuchi, Vijay Rajendran, Jacques-Eric Gottenberg, Alena Pechonkina, YingMeei Tan, Qi Gong, Katrien Van Beneden, Roberto Caporali
Publikováno v:
Rheumatology. 61
Background/Aims The preferential Janus kinase-1 inhibitor filgotinib (FIL) is approved to treat RA in Europe. We assessed FIL efficacy/safety in patients (pts) with inadequate response (IR) to biologic DMARDs (bDMARDs) in a long-term extension trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be024e2399a28c2ed1a80670cfa65a86
https://doi.org/10.1093/rheumatology/keac133.198
https://doi.org/10.1093/rheumatology/keac133.198
Autor:
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Eiji Sugiyama, Kunihiro Yamaoka, Kevin Winthrop, Alan Kivitz, Gerd R Burmester, Jacques-Eric Gottenberg, Mark C Genovese, Franziska Matzkies, Ying Guo, Deyuan Jiang, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Robin Besuyen, Tsutomu Takeuchi
Publikováno v:
Modern rheumatology. 33(1)
Objective Characterize safety of the Janus kinase-1 preferential inhibitor filgotinib (FIL) in Japanese patients with moderately to severely active rheumatoid arthritis (RA). Methods Data from three Phase 3 trials (NCT02889796, NCT02873936, and NCT02
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2164cb13861c88f081a8edcacb53cce
https://pubmed.ncbi.nlm.nih.gov/35365828
https://pubmed.ncbi.nlm.nih.gov/35365828